Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

baerhunter: An R package for the discovery and analysis of expressed non-coding regions in bacterial RNA-seq data.

Ozuna A, Liberto D, Joyce RM, Arnvig KB, Nobeli I.

Bioinformatics. 2019 Aug 16. pii: btz643. doi: 10.1093/bioinformatics/btz643. [Epub ahead of print]

PMID:
31418770
2.

Significant and Distinctive n-Grams in Oncology Notes: A Text-Mining Method to Analyze the Effect of OpenNotes on Clinical Documentation.

Rahimian M, Warner JL, Jain SK, Davis RB, Zerillo JA, Joyce RM.

JCO Clin Cancer Inform. 2019 Jun;3:1-9. doi: 10.1200/CCI.19.00012.

3.

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia.

Lampson BL, Kim HT, Davids MS, Abramson JS, Freedman AS, Jacobson CA, Armand PA, Joyce RM, Arnason JE, Rassenti LZ, Kipps TJ, Fein J, Fernandes SM, Hanna JR, Fisher DC, Brown JR.

Blood Adv. 2019 Apr 9;3(7):1167-1174. doi: 10.1182/bloodadvances.2018030221.

4.

PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation.

Armand P, Chen YB, Redd RA, Joyce RM, Bsat J, Jeter E, Merryman RW, Coleman KC, Dahi PB, Nieto Y, LaCasce AS, Fisher DC, Ng SY, Odejide OO, Freedman AS, Kim AI, Crombie JL, Jacobson CA, Jacobsen ED, Wong JL, Patel SS, Ritz J, Rodig SJ, Shipp MA, Herrera AF.

Blood. 2019 Jul 4;134(1):22-29. doi: 10.1182/blood.2019000215. Epub 2019 Apr 5.

PMID:
30952672
5.

Reduced-Intensity Conditioning Regimens, Prior Chronic Lymphocytic Leukemia, and Graft-Versus-Host Disease Are Associated with Higher Rates of Skin Cancer after Allogeneic Hematopoietic Stem Cell Transplantation.

Wu PA, Stern RS, Huang V, Liu KX, Chen CA, Tzachanis D, Joyce RM, Davis RB, Ho VT.

J Invest Dermatol. 2019 Mar;139(3):591-599. doi: 10.1016/j.jid.2018.08.025. Epub 2018 Oct 11.

PMID:
30316899
6.

Canonical PRC2 function is essential for mammary gland development and affects chromatin compaction in mammary organoids.

Michalak EM, Milevskiy MJG, Joyce RM, Dekkers JF, Jamieson PR, Pal B, Dawson CA, Hu Y, Orkin SH, Alexander WS, Lindeman GJ, Smyth GK, Visvader JE.

PLoS Biol. 2018 Aug 6;16(8):e2004986. doi: 10.1371/journal.pbio.2004986. eCollection 2018 Aug.

7.

Continuous positive airway pressure-associated cutaneous amoebiasis in an immunosuppressed patient.

Sells RE, Chen CA, Wong MT, Zimarowski MJ, Kirby JE, Joyce RM, Wu PA.

Br J Dermatol. 2016 Mar;174(3):625-8. doi: 10.1111/bjd.14231. Epub 2016 Jan 5.

PMID:
26474324
8.

Inherited CHST11/MIR3922 deletion is associated with a novel recessive syndrome presenting with skeletal malformation and malignant lymphoproliferative disease.

Chopra SS, Leshchiner I, Duzkale H, McLaughlin H, Giovanni M, Zhang C, Stitziel N, Fingeroth J, Joyce RM, Lebo M, Rehm H, Vuzman D, Maas R, Sunyaev SR, Murray M, Cassa CA.

Mol Genet Genomic Med. 2015 Sep;3(5):413-23. doi: 10.1002/mgg3.152. Epub 2015 May 10.

9.

Yttrium-90 ibritumomab tiuxetan followed by rituximab maintenance as treatment for patients with diffuse large B-cell lymphoma are not candidates for autologous stem cell transplant.

Arnason JE, Luptakova K, Rosenblatt J, Tzachanis D, Avigan D, Zwicker JI, Levine J, Kim M, Parker JA, Grant B, Joyce RM.

Acta Haematol. 2015;133(4):347-53. doi: 10.1159/000368291. Epub 2015 Feb 7.

PMID:
25677780
10.

Primary cardiac burkitt lymphoma presenting with abdominal pain.

Tzachanis D, Dewar R, Luptakova K, Chang JD, Joyce RM.

Case Rep Hematol. 2014;2014:687598. doi: 10.1155/2014/687598. Epub 2014 Nov 6.

11.

A 78-year-old man with acute myeloid leukemia (AML) and acute renal failure.

Tapper EB, Luptakova K, Joyce RM, Tzachanis D.

Am J Case Rep. 2014 Aug 30;15:364-7. doi: 10.12659/AJCR.890798.

12.

Rifaximin suppresses background intestinal 18F-FDG uptake on PET/CT scans.

Franquet E, Palmer MR, Gifford AE, Selen DJ, Chen YC, Sedora-Roman N, Joyce RM, Kolodny GM, Moss AC.

Nucl Med Commun. 2014 Oct;35(10):1026-31. doi: 10.1097/MNM.0000000000000170.

PMID:
25076161
13.
14.

MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells.

Stroopinsky D, Rosenblatt J, Ito K, Mills H, Yin L, Rajabi H, Vasir B, Kufe T, Luptakova K, Arnason J, Nardella C, Levine JD, Joyce RM, Galinsky I, Reiter Y, Stone RM, Pandolfi PP, Kufe D, Avigan D.

Cancer Res. 2013 Sep 1;73(17):5569-79. doi: 10.1158/0008-5472.CAN-13-0677. Epub 2013 Jul 18.

15.

External phenome analysis enables a rational federated query strategy to detect changing rates of treatment-related complications associated with multiple myeloma.

Warner JL, Alterovitz G, Bodio K, Joyce RM.

J Am Med Inform Assoc. 2013 Jul-Aug;20(4):696-9. doi: 10.1136/amiajnl-2012-001355. Epub 2013 Mar 20.

16.

Lenalidomide enhances anti-myeloma cellular immunity.

Luptakova K, Rosenblatt J, Glotzbecker B, Mills H, Stroopinsky D, Kufe T, Vasir B, Arnason J, Tzachanis D, Zwicker JI, Joyce RM, Levine JD, Anderson KC, Kufe D, Avigan D.

Cancer Immunol Immunother. 2013 Jan;62(1):39-49. doi: 10.1007/s00262-012-1308-3. Epub 2012 Jun 24.

17.

Interleukin-2 and regulatory T cells in graft-versus-host disease.

Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP 3rd, Armand P, Cutler C, Ho VT, Treister NS, Bienfang DC, Prasad S, Tzachanis D, Joyce RM, Avigan DE, Antin JH, Ritz J, Soiffer RJ.

N Engl J Med. 2011 Dec 1;365(22):2055-66. doi: 10.1056/NEJMoa1108188.

18.

PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine.

Rosenblatt J, Glotzbecker B, Mills H, Vasir B, Tzachanis D, Levine JD, Joyce RM, Wellenstein K, Keefe W, Schickler M, Rotem-Yehudar R, Kufe D, Avigan D.

J Immunother. 2011 Jun;34(5):409-18. doi: 10.1097/CJI.0b013e31821ca6ce.

19.

A case of HIV-negative primary effusion lymphoma treated with bortezomib, pegylated liposomal doxorubicin, and rituximab.

Siddiqi T, Joyce RM.

Clin Lymphoma Myeloma. 2008 Oct;8(5):300-4. doi: 10.3816/CLM.2008.n.042.

PMID:
18854285
20.

Peripheral blood progenitor cell product contains Th1-biased noninvariant CD1d-reactive natural killer T cells: implications for posttransplant survival.

Shaulov A, Yue S, Wang R, Joyce RM, Balk SP, Kim HT, Avigan DE, Uhl L, Sackstein R, Exley MA.

Exp Hematol. 2008 Apr;36(4):464-72. doi: 10.1016/j.exphem.2007.12.010. Epub 2008 Feb 8.

21.

Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248.

Treon SP, Hunter ZR, Matous J, Joyce RM, Mannion B, Advani R, Cook D, Songer J, Hill J, Kaden BR, Sharon D, Steiss R, Leleu X, Branagan AR, Badros A.

Clin Cancer Res. 2007 Jun 1;13(11):3320-5.

22.

False-positive axillary lymph node on FDG-PET/CT scan resulting from immunization.

Williams G, Joyce RM, Parker JA.

Clin Nucl Med. 2006 Nov;31(11):731-2.

PMID:
17053400
23.

Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation.

Antin JH, Guinan EC, Avigan D, Soiffer RJ, Joyce RM, Martin VJ, Molrine DC.

Biol Blood Marrow Transplant. 2005 Mar;11(3):213-22.

24.

A phase I-II study of rituximab, ifosfamide, mitoxantrone and etoposide (R-IME) for B cell non-Hodgkin's lymphoma prior to and after high-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT).

Joyce RM, Regan M, Ottaway J, Umiel T, Tetreault JC, Levine J, McDermott D, Hurley D, Giallombardo N, Smith T, Lamontagne D, Uhl L, Avigan D.

Ann Oncol. 2003;14 Suppl 1:i21-7.

PMID:
12736227
25.

Zevalin: 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin's lymphoma.

Krasner C, Joyce RM.

Curr Pharm Biotechnol. 2001 Dec;2(4):341-9. Review.

PMID:
11762415
26.

Rituximab and ifosfamide, mitoxantrone, etoposide (RIME) with Neupogen support for B-cell non-Hodgkin's lymphoma prior to high-dose chemotherapy with autologous haematopoietic transplant.

Joyce RM, Kraser CN, Tetrealt JC, Giallombardo N, McDermott D, Levine J, Umiel T, Regan M, Hurley D, Uhl L, Avigan D.

Eur J Haematol Suppl. 2001 Jul;64:56-62.

PMID:
11486404
27.

Slow-release aspirin and prostaglandin inhibition.

Roberts MS, Joyce RM, McLeod LJ, Vial JH, Seville PR.

Lancet. 1986 May 17;1(8490):1153-4. No abstract available.

PMID:
2871403
28.

Malignant melanoma: analysis by DNA flow cytometry.

Wass J, Zbroja RA, Young GA, Vincent PC, Joyce RM, Croaker G.

Pathology. 1985 Jul;17(3):475-80.

PMID:
4069767
29.

Semi-solid cultures of primary melanomas and their correlation with histopathological features.

Vincent PC, Joyce RM, Croaker G, Young GA, Milton GW, McCarthy WH.

Pathology. 1985 Apr;17(2):360-4.

PMID:
4047740
30.

Comparisons of the growth in tissue culture of primary and metastatic melanoma.

Joyce RM, Vincent PC, Croaker GM, Young GA.

Pathology. 1985 Apr;17(2):355-9.

PMID:
4047739
31.

Prudent practices for disposal of chemicals from laboratories.

Joyce RM.

Science. 1984 May 4;224(4648):449-52.

PMID:
17753752
33.

Science and religion.

Joyce RM.

Science. 1982 Apr 16;216(4543):242. No abstract available.

PMID:
17832721
34.

The action of alkali on cyclohexanones.

CAIRNS TL, JOYCE RM, SCHREIBER RS.

J Am Chem Soc. 1948 May;70(5):1689. No abstract available.

PMID:
18861742

Supplemental Content

Loading ...
Support Center